Heron Therapeutics Files 8-K for Material Agreement

TL;DR

HRTX signed a big deal on 8/22, filed 8-K on 8/28. Details TBD.

AI Summary

Heron Therapeutics, Inc. (HRTX) filed an 8-K on August 28, 2025, reporting a material definitive agreement entered into on August 22, 2025. The filing also includes financial statements and exhibits related to this agreement. Specific details of the agreement, including parties involved and financial implications, are not fully disclosed in the provided text.

Why It Matters

This filing indicates a significant new development or contract for Heron Therapeutics, which could impact its business operations, financial performance, and future strategic direction.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant financial or operational implications, but the lack of specific details in the provided text necessitates a medium risk assessment.

Key Players & Entities

• Heron Therapeutics, Inc. (company) — Registrant
• August 22, 2025 (date) — Date of earliest event reported
• August 28, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• 94-2875566 (ein) — I.R.S. Employer Identification No.
• 100 Regency Forest Drive , Suite 300 , Cary , NC 27518 (address) — Address of principal executive offices
• 858-251-4400 (phone) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share HRTX The Nasdaq Capital M
• $614,550.50 — nthly base rent under the Lease will be $614,550.50 for the first 12-month term, which will

Filing Documents

• hrtx-20250822.htm (8-K) — 58KB
• 0000950170-25-112048.txt ( ) — 194KB
• hrtx-20250822.xsd (EX-101.SCH) — 50KB
• hrtx-20250822_htm.xml (XML) — 5KB

01 Entry Into a Material Definitive Agreement

Item 1.01 Entry Into a Material Definitive Agreement. Heron Therapeutics, Inc., a Delaware corporation (the " Company "), entered into an Office Lease Agreement (the " Lease "), dated as of August 22, 2025, with USEF HCG Fenton LLC, a Delaware limited liability company (the " Landlord "). The Lease is for the Company's new corporate headquarters, which is approximately 16,837 rentable square feet (the " Premises ") at 25 Fenton Main Street, Cary, North Carolina, 27511 (the " Building "). The Lease provides for a term of approximately one hundred eleven months. Under the terms of the Lease, the Tenant has the option to extend the Lease one time for a period of eighty-four additional months, by providing written notice to the Landlord not more than 18 months nor less than 12 months prior to the expiration date. In addition, during the term of the Lease, the Lease also provides the Tenant with a one-time "right of first refusal" with respect to any vacant space contiguous to the Premises, when such space becomes available for lease, subject to any terms provided by the Landlord in connection with the offer to lease such space. Beginning on the Commencement Date (the " Term Commencement Date "), the Company's monthly base rent under the Lease will be $614,550.50 for the first 12-month term, which will increase by a certain percentage per each subsequent 12-month term, and will also be responsible for paying its proportionate share of operating costs; provided, that base rent and estimated operating costs will be abated during a certain number of months after the Term Commencement Date. The Lease contains customary representations, warranties, and covenants. The foregoing description of the Lease is not complete and is qualified in its entirety by reference to the complete terms and conditions of the Lease. A copy of the Lease will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the period ending September 30, 2025.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Heron Therapeutics, Inc. Date: August 28, 2025 /s/ Ira Duarte Ira Duarte Executive Vice President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR